50results about How to "Reduce endotoxin" patented technology

The invention provides eye drops and a preparation method thereof, and relates to the eye drops. The invention provides the eye drops which have the advantages of shorter action time, lower cost, better effect and capacity of resisting corneal neovascularization and quickly repairing epithelium compared with the conventional eye drops, and a preparation method thereof. The eye drops comprise the following components in percentage by volume: 0.1 to 5 percent of bovine serum, 5 to 15 percent of thickener, 1 to 5 percent of pH regulation solution, 0.1 to 2 percent of osmotic pressure buffer, 0.5to 2 percent of antibiotic, 5 to 30 percent of original solution of kallikrein-binding protein (SA3K) and the balance of balanced salt solution. According to a prescription of the eye drops, the preparation method comprises the following steps of: adding the thickener, the bovine serum, the antibiotic and the original solution of SA3K into the balanced salt solution; uniformly mixing; regulating the pH value to be 7.2 to 7.4 by using the pH regulator; regulating the osmotic pressure to be 350 to 380mOsm/L by using the osmotic pressure buffer; and filtering and degerming by using a membrane toobtain the SA3K eye drops.

Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm animal productivity.

The invention discloses application of chitosan oligosaccharide as regulating agent for regulating animal intestinal flora disturbance, the chitosan oligosaccharide, a mixture containing the chitosanoligosaccharide and corresponding application. The polymerization degree of the chitosan oligosaccharide is 2 to 20, so that the intestinal flora disturbance caused by obesity or diabetes or an unreasonable diet structure can be regulated, growth of beneficial bacteria such as Akkermansia, Bifidobacterium and Lactobacillus of an intestinal tract is promoted, and proliferation of harmful bacteriasuch as Desulfovibrio and Helicobacter is obviously inhibited. The invention provides an application method of a clinically-acceptable medicinal preparation or health-care food which is made by usingthe chitosan oligosaccharide alone or a composition prepared from the chitosan oligosaccharide and the beneficial bacteria according to a conventional process. By utilizing the chitosan oligosaccharide, prevention and control of the intestinal disturbance caused by the diabetes, the obesity and the inflammatory bowel disease have an active application value.

The present disclosure provides a polymer comprising a derivative of chitosan, wherein the derivative is zwitterionic, as well as methods of using the polymer. In addition, the present disclosure provides a nanoparticle structure comprising a derivative of chitosan and a dendrimer, as well as methods of utilizing the nanoparticle structure.

The invention discloses an eyedrop which has the pH value of 7.2-7.4 and comprise the following components in percentage by volume: 10%-15% of UNC5B recombinant protein, 0.1%-5% of bovine serum, 5%-15% of a thickener, 1%-5% of a pH regulator and 0.5%-2% of antibiotics; a solvent is a balanced salt solution. A preparation method of the eye drops is simple, reliable and easy to perform; the eye drops are simple in component, relatively low in cost and convenient to prepare.

The invention discloses an application of Lactobacillus rhamnosum LRX-01 in preparation of a product for preventing and treating human or mammal diseases caused by high temperature. When a heat stress test is carried out on a mouse, the inventor of the invention finds that the survival time of the mouse subjected to high-temperature treatment can be obviously prolonged by pretreating the mouse with the Lactobacillus rhamnosum LRX-01, and the survival time of the mouse subjected to high-temperature treatment can be obviously prolonged by treating the mouse with the Lactobacillus rhamnosum LRX-01, so that the survival time of the mouse subjected to high-temperature treatment can be obviously prolonged, and the application of the Lactobacillus rhamnosum LRX-01 in preparation of the product for preventing and treating the human or mammal diseases caused by high temperature can be obviously prolonged. The lactobacillus rhamnosus LRX-01 has the advantages that the lactobacillus rhamnosus LRX-01 can be used for preventing and treating human or mammal diseases caused by high temperature, the serum inflammatory factors and endotoxin of the lactobacillus rhamnosus LRX-01 can be reduced, the intestinal injury caused by heat stress can be relieved, and the results show that the lactobacillus rhamnosus LRX-01 has potential application value in the aspect of preventing and treating the human or mammal diseases caused by high temperature.

The invention relates to a composite bacterial cellulose dressing based on a controllable nanofiber space structure and a preparation method thereof. The preparation method comprises the steps of: firstly, dropwise adding gelatin-based aqueous solution into a non-woven material containing a protein component; after drying, dropwise adding culture bacterium solution onto the non-woven material; until the composite non-woven material adsorbs the culture bacterium solution to be saturated, adding fermentation culture solution to carry out standing culture; and finally, immersing a compound obtained by standing culture into triton aqueous solution with the concentration of 0.1 to 1wt% for purification, and drying to obtain the non-woven material composite bacterial cellulose dressing. The prepared dressing has a density structure, specifically, bacterial cellulose nanofibers are distributed on non-woven micron-sized fibers, and the distribution and the density degree of the nanofibers areadjustable. The prepared non-woven material composite bacterial cellulose dressing prepared by the invention has good biocompatibility, mechanical properties and wound exudate absorption performance,and has huge application prospects in the biomedical fields of a wound dressing, a human body repair material, a tissue engineering material and the like.

The invention provides a purifying method of medium molecular weight hydroxyethyl starch. The method comprises the following steps: 1, mixing an aqueous solution of medium molecular weight hydroxyethyl starch obtained in an ultrafiltration step of a medium molecular weight hydroxyethyl starch preparation technology with C1-C3 monohydric alcohol to precipitate the medium molecular weight hydroxyethyl starch from the aqueous solution; and 2, separating the medium molecular weight hydroxyethyl starch precipitated in step 1 to obtain purified medium molecular weight hydroxyethyl starch. The invention also provides the medium molecular weight hydroxyethyl starch obtained through the method. The method has industrialized values and can improve the internal quality of a product. The method has the advantages of reduction of the bacterial endotoxin and glycol level of the finished product, economy, energy saving, environmental protection and energy consumption reduction, and is suitable for real needs of the industrialized mass production.

The invention discloses a fusion protein of recombinant clostridium histolyticum type I collagenase. The fusion protein comprises the clostridium histolyticum type I collagenase and tag protein connected to the N end of the clostridium histolyticum type I collagenase. The tag protein comprises a calmodulin binding peptide (CBP) and a streptococcus avidin binding peptide (SBP) which are connected in series. The invention further provides a preparation method and application of the fusion protein of the recombinant clostridium histolyticum I type collagenase. The CBP-SBP is used as a fusion tag, soluble expression of clostridium histolyticum I type collagenase (ColG) can be efficiently promoted, inclusion body renaturation is avoided, purification is facilitated, the production cost is reduced, and the requirements of industrial production can be met.

The invention discloses and provides a recombinant histolytic clostridium type II collagenase. The recombinant histolytic clostridium type II collagenase comprises a histolytic clostridium type II collagenase and a tag protein connected to an N end of the histolytic clostridium type II collagenase, the tag protein comprises fasciola hepatica calcium binding protein (Fh8); preferably, the amino acid sequence of the fasciola hepatica calcium binding protein is SEQ ID NO: 2. The invention also provides an expression vector and recombinant engineering bacteria for expressing the recombinant clostridium histolyticum type II collagenase, and also provides a preparation method of the clostridium histolyticum type II collagenase. The recombinant clostridium histolyticum type II collagenase can be efficiently expressed, does not form inclusion bodies, is easy to separate and purify, and is beneficial to industrial production of the clostridium histolyticum type II collagenase.

The invention relates to the technical field of sludge treatment, in particular to a harmless treatment method for sludge in an urban sewage treatment plant. The invention provides a sludge harmless treatment method which comprises the following steps of: firstly, fully mixing water-containing sludge with magnesite powder, adding potassium monopersulfate composite salt, fully aerating the sludge, introducing the sludge into a reactor with a UV-C ultraviolet lamp for continuous digestion, and finally dehydrating and drying the obtained clean sludge. The sludge harmless treatment method is simple in process, controllable in cost and thorough in harmless treatment, development and application of finally obtained clean sludge powder are facilitated, and the obtained sludge powder can be used for manufacturing cement, bricks, tiles, fertilizers and the like.

The invention discloses a bovine pasteurella multocida inactivated vaccine and a preparation method thereof, and belongs to the technical field of veterinary biological products. The vaccine comprisesantigens and adjuvants, wherein the antigens are a bovine pasteurella multocida capsule type B C45-2 strain and a C47-2 strain. The preparation method comprises the following steps: performing inoculated culture on strains, performing shake culture, streaking a culture on an agar plate for culture, selecting bacterial colonies, inoculating a fresh blood slant with the selected bacterial colonies,performing culturing to obtain primary seeds, inoculating a culture medium with the primary seeds, and performing shake culture to obtain secondary seeds; mixing the secondary seeds, and performing inoculated culture to obtain zymophyte liquid, wherein the culture process is optimized, so that the antigen quantity is multiplied; and performing centrifuging to remove endotoxin, transferring bacterial sludge into normal saline, adding formaldehyde, performing inactivating, adding aluminum hydroxide glue, thiomersalate and phenol, performing full oscillating, and performing sub-packaging. The dosage of the bovine pasteurella multocida inactivated vaccine for immunizing a calf is 2-3mL and is less than the existing injection dosage, the side effect is greatly reduced, and the bovine pasteurella multocida inactivated vaccine has popularization and application values in the fields of bovine pasteurella multocida inactivated vaccines and even all bacterial culture processes.

The invention belongs to the field of skin medicine, and particularly relates to a hypoallergenic and anti-aging yak collagen compound. The invention provides the yak collagen with low endotoxin and low sensitization, and the yak collagen is low in cytotoxicity, can promote cell proliferation and cell adhesion, and has good properties such as oxidation resistance and aging resistance. Meanwhile, the yak collagen composition containing yak collagen, hyaluronic acid, dipotassium glycyrrhizinate, acetyl hexapeptide-8, ellagic acid, a Salix alba bark extract, nicotinamide, vitamin E and resveratrol is obtained through screening, and the yak collagen composition has low sensitization and more excellent antioxidant and anti-aging performance, and can be widely applied to the field of cosmetics or dermatology.